1. Introduction

Systemic risk in biotechnology refers to the possibility that a failure, accident, technological malfunction, regulatory weakness, or harmful biological event in one part of the biotechnology sector may spread across interconnected institutions, industries, populations, ecosystems, or national borders, creating widespread and potentially irreversible consequences.

Unlike ordinary risks, which generally affect an individual, company, laboratory, or specific research project, systemic risks can threaten entire biological, economic, healthcare, agricultural, and environmental systems.

For example:

• A genetically modified organism may escape from a controlled research facility and affect surrounding ecosystems.
• A failure in vaccine manufacturing may disrupt national immunisation programmes.
• A cyberattack on genomic databases may expose millions of individuals' genetic information.
• An error in AI-assisted drug development may affect multiple pharmaceutical companies and healthcare institutions.
• A laboratory accident involving a dangerous pathogen may create a public-health emergency extending beyond national borders.

Systemic risk is therefore an important subject of biotechnology law because traditional regulatory frameworks often focus on individual products, organisations, and identifiable injuries rather than interconnected failures.

2. Meaning and Nature of Systemic Risk

Systemic risk has five important characteristics.

A. Interconnectedness

Biotechnology companies, laboratories, hospitals, research institutions, regulators, pharmaceutical manufacturers, and supply chains depend on one another. A failure in one institution can affect several others.

B. Contagion effect

A biological, technological, or financial failure may spread beyond its original location.

C. Cascading consequences

One incident can trigger multiple secondary failures. For example, contamination of biological materials may disrupt manufacturing, clinical trials, medicine distribution, and public confidence.

D. Uncertainty

Biological systems are complex. Some consequences of genetic modification, synthetic biology, or environmental release may not be immediately predictable.

E. Potential irreversibility

Certain environmental or genetic consequences may persist for generations or become difficult to reverse.

3. Major Sources of Systemic Risk in Biotechnology

A. Genetic engineering and synthetic biology

Genetic engineering creates risks when modified organisms interact with natural ecosystems. Uncontrolled release, unintended genetic transfer, and ecological disruption may produce consequences beyond the original research project.

B. Pharmaceutical manufacturing

Contamination, manufacturing defects, inadequate quality control, and failures in critical pharmaceutical supply chains can affect large populations.

C. Artificial intelligence in biotechnology

AI systems used for genetic analysis, drug discovery, disease prediction, and clinical decision-making may generate errors that spread across multiple institutions using the same model or dataset.

D. Genetic databases and biological information

Large-scale genomic databases create interconnected privacy and cybersecurity risks. A single security breach may expose sensitive genetic information affecting individuals and their relatives.

E. Laboratory and biosecurity failures

Failures in pathogen containment, laboratory safety, biological material transportation, or institutional supervision may create risks to public health and national security.

F. Agricultural biotechnology

Genetically modified crops, seed distribution systems, and biological pest-control technologies can create widespread agricultural and ecological consequences if regulatory safeguards fail.

4. Legal Principles Governing Systemic Risk

A. Precautionary Principle

The precautionary principle requires governments and regulatory authorities to take preventive action where an activity presents a threat of serious environmental or public-health harm, even when scientific evidence is incomplete.

In biotechnology, this principle is particularly important for:

• Gene-drive organisms.
• Genetically modified crops.
• Synthetic microorganisms.
• Experimental biological products.
• Environmental release of engineered organisms.

The principle is recognised in Principle 15 of the Rio Declaration and incorporated into the framework of the Cartagena Protocol on Biosafety.

B. Polluter Pays Principle

Under this principle, organisations responsible for environmental damage must bear the costs of preventing, controlling, and remedying that damage.

For biotechnology companies, potential obligations include:

• Environmental restoration.
• Compensation for affected communities.
• Remediation of biological contamination.
• Monitoring of affected ecosystems.
• Costs of emergency containment.

C. Absolute Liability

Where an enterprise conducts inherently hazardous activities, Indian law may impose absolute liability for harm caused by those activities, without allowing the traditional exceptions available under strict liability.

This principle is particularly relevant to dangerous biological research and hazardous industrial biotechnology operations.

D. Intergenerational Equity

Biotechnology activities must be regulated with consideration for future generations. Genetic contamination, biodiversity destruction, and long-lasting environmental changes may impose costs on people who were not involved in the original activity.

E. Public Trust Doctrine

The government acts as a trustee of natural resources, including biodiversity, forests, water, and ecological systems. It cannot disregard its responsibility to protect these resources merely because biotechnology activities offer commercial or scientific benefits.

5. Important Case Laws on Systemic Risk

The following decisions establish important legal principles relevant to systemic risk. Some concern biotechnology directly, while others provide broader environmental and public-safety doctrines applicable to biotechnology.

Case 1: M.C. Mehta v. Union of India (Oleum Gas Leak Case), 1987

SUPREME COURT OF INDIA · 1987

Background:

An oleum gas leak occurred at an industrial facility in Delhi, causing injuries and raising serious questions about the safety obligations of enterprises conducting hazardous activities.

Judgment:

The Supreme Court developed the principle of absolute liability for enterprises engaged in hazardous or inherently dangerous activities.

Legal significance:

1. Hazardous enterprises have a non-delegable duty to ensure public safety.
2. Liability cannot be avoided through traditional exceptions to strict liability.
3. Compensation must reflect the magnitude and capacity of the enterprise.
4. Industrial development cannot override public safety.

Application to biotechnology:

A biotechnology enterprise operating dangerous pathogen facilities or hazardous biological manufacturing processes may face substantial liability if its operations cause widespread harm.

Case 2: Vellore Citizens' Welfare Forum v. Union of India (1996)

SUPREME COURT OF INDIA · (1996) 5 SCC 647

Background:

Industrial pollution from tanneries in Tamil Nadu caused serious environmental damage, particularly to water resources and agricultural land.

Judgment:

The Supreme Court recognised the precautionary principle and polluter pays principle as essential components of Indian environmental law.

Legal significance:

• Environmental protection must be integrated into development decisions.
• Scientific uncertainty does not automatically justify inaction.
• Polluters may be required to compensate affected persons and restore environmental damage.

Application to biotechnology:

If genetically modified organisms contaminate surrounding agricultural ecosystems, regulators and courts may require preventive measures, liability assessment, and ecological restoration.

Case 3: A.P. Pollution Control Board v. Prof. M.V. Nayudu (1999)

SUPREME COURT OF INDIA · (1999) 2 SCC 718

Background:

The dispute concerned the establishment of a hazardous industry near drinking-water resources and the scientific assessment of environmental risks.

Judgment:

The Supreme Court emphasised the importance of scientific expertise in environmental decision-making, particularly where scientific uncertainty exists.

Legal significance:

1. Environmental decisions require reliable scientific evidence.
2. Expert institutions have an important role in risk assessment.
3. Courts must carefully examine technical uncertainty.
4. Regulatory authorities must not disregard potential environmental consequences.

Application to biotechnology:

Regulators approving gene-editing experiments, genetically engineered organisms, or synthetic biological systems must rely on scientifically credible risk assessments.

Case 4: Aruna Rodrigues v. Union of India (2012)

SUPREME COURT OF INDIA · GMO BIOSAFETY LITIGATION

Background:

The petitioners raised concerns regarding the environmental release and field trials of genetically modified organisms in India.

They questioned whether existing regulatory safeguards adequately protected human health, biodiversity, and environmental safety.

Judgment and proceedings:

The Supreme Court addressed biosafety concerns and the need for appropriate scientific evaluation, regulatory supervision, and safeguards in GMO field trials.

The proceedings contributed significantly to scrutiny of India's genetically modified crop approval system.

Legal significance:

• GMO approvals require scientific scrutiny.
• Environmental and public-health risks must be considered.
• Regulatory supervision must be effective.
• Transparency and independent scientific evaluation are important.

Application to systemic risk:

A genetically modified organism may create consequences beyond an individual farm or research facility. Therefore, its assessment must consider potential effects on connected agricultural and ecological systems.

Case 5: Gene Campaign v. Union of India (2024)

SUPREME COURT OF INDIA · 2024 INSC 545

Background:

The litigation concerned the approval process for the environmental release of genetically modified mustard DMH-11.

The dispute raised questions about regulatory independence, scientific assessment, environmental safety, and the adequacy of the approval process.

Judgment:

The Supreme Court delivered a split verdict.

• Justice B.V. Nagarathna questioned the approval and emphasised deficiencies in the consideration of environmental and health risks.
• Justice Sanjay Karol took a different view regarding the regulatory process and scientific development.

The Court directed the Union Government to formulate a national policy on genetically modified crops in consultation with stakeholders. The disputed issues were referred for consideration by a larger Bench.

Legal significance:

1. Biotechnology approvals require detailed risk assessment.
2. Regulatory institutions must maintain scientific independence.
3. Environmental release requires adequate consideration of ecological consequences.
4. Public participation and transparency are important.
5. Scientific uncertainty must be addressed through appropriate precautionary safeguards.

Application to systemic risk:

The decision is particularly important because the environmental release of a genetically modified crop may affect biodiversity, traditional agricultural varieties, and interconnected ecosystems.

Case 6: M.C. Mehta v. Union of India (Ganga Pollution Case)

Background:

The litigation concerned industrial pollution discharged into the River Ganga, including pollution caused by industrial establishments.

Legal significance:

The Supreme Court reinforced the responsibility of industries to prevent environmental pollution and recognised that economic activity cannot justify continuing environmental damage.

Application to biotechnology:

Biotechnology manufacturing facilities must ensure safe disposal of biological waste, chemicals, and contaminated materials. A failure may affect water resources and surrounding communities.

Case 7: Monsanto Canada Inc. v. Schmeiser (2004)

SUPREME COURT OF CANADA · 2004 SCC 34

Background:

The dispute concerned patented genetically modified canola plants found growing on a Canadian farmer's land.

Judgment:

The Supreme Court of Canada examined patent infringement involving genetically modified plant technology and the use of patented genes and cells.

Legal significance:

The decision addressed:

• Intellectual property rights in biotechnology.
• Ownership and use of genetically modified inventions.
• The distinction between possession and use of patented technology.

Application to systemic risk:

The case illustrates how genetically engineered biological materials can create legal disputes extending beyond the original research or commercial setting.

Note: This is a comparative intellectual-property decision, not a direct ruling on systemic environmental liability.

6. Indian Legal and Regulatory Framework

Several Indian laws collectively regulate risks that may develop into systemic biotechnology failures.

India's biotechnology regulatory framework includes the Genetic Engineering Appraisal Committee (GEAC), Review Committee on Genetic Manipulation (RCGM), Institutional Biosafety Committees (IBSCs), and other competent authorities.

The 1989 Rules regulate the manufacture, import, use, research, and release of genetically engineered organisms and hazardous microorganisms.

7. International Legal Framework

A. Cartagena Protocol on Biosafety, 2000

The Cartagena Protocol on Biosafety is one of the most important international instruments for managing biotechnology-related environmental risks.

Its principal objectives include:

• Safe handling and transportation of living modified organisms.
• Prevention of adverse effects on biodiversity.
• Consideration of risks to human health.
• Advance informed agreement for relevant transboundary movements.
• Scientific risk assessment and risk management.
• Emergency response following accidental release.

Articles 15, 16 and 17 are particularly relevant to risk assessment, risk management, and unintentional transboundary movements.

B. Convention on Biological Diversity, 1992

The Convention requires countries to protect biological diversity and regulate risks associated with biotechnology.

Article 8(g) is particularly relevant to regulating, managing, and controlling risks associated with living modified organisms.

C. Nagoya–Kuala Lumpur Supplementary Protocol, 2010

This instrument addresses liability and redress associated with damage to biodiversity resulting from living modified organisms.

It provides an international framework for response measures where qualifying biodiversity damage occurs.

8. Corporate Liability for Systemic Biotechnology Risk

Biotechnology companies have responsibilities extending beyond obtaining initial regulatory approval.

Their legal obligations may include:

1. Conducting comprehensive safety assessments.
2. Maintaining appropriate laboratory containment.
3. Monitoring adverse biological effects.
4. Maintaining product traceability.
5. Reporting accidents and safety incidents.
6. Protecting genetic and biological information.
7. Maintaining emergency-response procedures.
8. Providing compensation where legally liable.
9. Preventing contamination of surrounding ecosystems.
10. Maintaining appropriate insurance and financial safeguards.

Corporate directors and senior management may also face liability where statutory violations, negligence, or other legally recognised grounds are established.

9. Regulatory Challenges in Controlling Systemic Risk

There are several major legal challenges.

1. Fragmented regulatory authority: Different agencies supervise environmental safety, healthcare, pharmaceutical production, data protection, and agricultural biotechnology.

2. Scientific uncertainty: Regulatory authorities may lack sufficient information about long-term biological consequences.

3. Cross-border enforcement: Biological materials and genetic information may move between countries, creating jurisdictional conflicts.

4. Delayed harm: Environmental and genetic consequences may become apparent years after the original activity.

5. Difficulty establishing causation: It may be difficult to identify which company, institution, or biological process caused widespread harm.

6. Technological concentration: Multiple institutions may depend on the same AI system, genetic database, manufacturing supplier, or biological platform. One failure can therefore affect the entire network.

10. Suggestions for Strengthening Systemic Risk Regulation

A comprehensive legal framework should introduce:

• Mandatory systemic risk assessments before high-risk biotechnology activities.
• Independent biosafety audits.
• Continuous environmental monitoring.
• Mandatory reporting of serious incidents.
• Stronger laboratory accreditation.
• National biological emergency-response mechanisms.
• Cross-border cooperation and information-sharing.
• Public access to relevant safety information.
• Strict accountability for negligent regulatory approvals.
• Financial compensation and environmental restoration mechanisms.

A particularly important reform would be the introduction of a Biotechnology Systemic Risk Management Framework that examines not only individual products but also their cumulative effects on interconnected biological, economic, environmental, and healthcare systems.

11. Critical Legal Analysis

Traditional biotechnology regulation generally follows a product-based approach. Authorities examine whether a particular organism, medicine, treatment, or technological process satisfies prescribed safety requirements.

However, systemic risk requires a broader approach.

For example, a genetically modified crop may individually satisfy regulatory requirements, but large-scale cultivation could create additional ecological, agricultural, or economic consequences.

Similarly, an AI-based genetic testing system may be individually certified, but widespread dependence on the same inaccurate algorithm could create population-wide consequences.

Therefore, modern biotechnology law should move from isolated product regulation towards integrated risk governance.

Three legal approaches are especially important:

1. Preventive governance: Identify and reduce risks before widespread harm occurs.
2. Adaptive governance: Continuously review regulatory decisions as scientific evidence develops.
3. Collective accountability: Ensure that companies, research institutions, regulators, and governments accept responsibility according to their respective legal duties.

12. Conclusion

Systemic risk is one of the most significant emerging challenges in biotechnology law. Its consequences may extend beyond individual victims, companies, laboratories, or national boundaries.

The decisions in M.C. Mehta, Vellore Citizens' Welfare Forum, A.P. Pollution Control Board v. M.V. Nayudu, Aruna Rodrigues, and Gene Campaign establish important foundations for preventive regulation, scientific accountability, environmental protection, and biosafety governance.

The central legal principle is that biotechnology innovation must not be allowed to create uncontrolled risks for society, public health, biodiversity, or future generations.

Ultimately, the objective of systemic risk regulation is not to prevent scientific progress but to ensure that scientific progress remains legally accountable, environmentally sustainable, scientifically defensible, and socially responsible.

13. Important Case Laws: Quick Revision Table

Academic note: These cases do not all establish a standalone doctrine of systemic risk. They provide related doctrines that can be applied to systemic biotechnology risks. The 2024 Gene Campaign decision was a split verdict, and its unresolved issues and subsequent larger-Bench proceedings must be considered when citing its legal effect.

Research conclusion: Systemic risk in biotechnology should be treated as an independent subject of regulatory governance, combining environmental law, constitutional law, administrative accountability, public-health law, corporate liability, intellectual property, and international biosafety law.